Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone deacetylases 1, 2, 3, and 11 are nuclear enzymes in the HDAC family that catalyze the removal of acetyl groups from lysine residues, playing a central role in the repression of gene transcription through chromatin condensation. HDAC1, 2, and 3 share high sequence homology and are found primarily in multi-protein complexes regulating gene silencing, cell cycle progression, and cellular differentiation. HDAC11, the only member of class IV, has functions distinct from other classes and has been implicated in immune regulation and mRNA splicing. Dysregulation of these enzymes is associated with oncogenesis and other disease states; thus, their inhibition is a key focus in epigenetic therapy development.
Inhibition of histone deacetylation, leading to increased acetylation of histones and relaxation of chromatin structure, facilitating gene expression. Modulation of non-histone protein acetylation affecting stability, localization, and function of transcription factors and other cellular proteins.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone deacetylase 1, 2, 3, and 11 (HDAC1, HDAC2, HDAC3, HDAC11).